What To Look Out For At ACC
Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.
You may also be interested in...
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June
Sanofi attorneys describe three possible outcomes of fight over injunction and validity of Repatha patents, and contrast litigation to other patent disputes where innovators did not seek removal of innovator product from market.
Phase III Boost For Esperion But Does It Own Its Destiny?
Esperion will be allowed to enroll patients on high dose statins into the Phase III pivotal trial of its cholesterol lowering drug bempedoic acid, but with competing products ahead in the race, the product faces an uphill battle for market share even if it does garner approval.